


REMARKS

Upon entry of this amendment, claims 1, 4-13, 15-16, 23-26, 28-30, 32-36 and 39-62 will be pending in this application. Amendments were made to claims 15, 16 and 39 and new claim 62 was added. No new matter has been added by this amendment.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By



Robert W. Hahl, Ph.D.  
Reg. No. 33,893  
Telephone: 703.905.2251  
Fax: 703.905.2500

RWH/jrh

1600 Tysons Boulevard  
McLean, Virginia 22102  
Phone: (703) 905-2118

Enclosures: Appendix

**APPENDIX****Version with Markings to Show Changes Made****IN THE SPECIFICATION:**

Priority claim has been added to the first page.

**IN THE CLAIMS:**

15. (Amended) An enteral formulation for nasogastric delivery as in claim 14 wherein the carrier is a [soluble] non-starch polysaccharide.

16. (Amended) An enteral formulation for nasogastric delivery as in claim 15 wherein the [soluble] non-starch polysaccharide is selected from the group consisting of inulin, pectin, chitin,  $\beta$  glucans, mucilages, agar, carageenans, alginates and gums including guar, arabic, xanthan, tragacanth, locust bean and psyllium.

39. (Amended) A method of elevating the level of [SCFA] a fatty acid in the colon of a human or animal, including the step of delivering a fatty delivery agent in a physiologically acceptable medium through a feeding tube to elevate the level of [SCFA,] the fatty acid, the fatty acid delivery agent being a fatty acid covalently bonded to a carrier molecule by a bond hydrolysable in the colon to thereby release the fatty acid.

New claim 62 was added.